» Articles » PMID: 30456386

LATS1 and LATS2 Suppress Breast Cancer Progression by Maintaining Cell Identity and Metabolic State

Abstract

Deregulated activity of LArge Tumor Suppressor (LATS) tumor suppressors has broad implications on cellular and tissue homeostasis. We examined the consequences of down-regulation of either LATS1 or LATS2 in breast cancer. Consistent with their proposed tumor suppressive roles, expression of both paralogs was significantly down-regulated in human breast cancer, and loss of either paralog accelerated mammary tumorigenesis in mice. However, each paralog had a distinct impact on breast cancer. Thus, LATS2 depletion in luminal B tumors resulted in metabolic rewiring, with increased glycolysis and reduced peroxisome proliferator-activated receptor γ (PPARγ) signaling. Furthermore, pharmacological activation of PPARγ elicited LATS2-dependent death in luminal B-derived cells. In contrast, LATS1 depletion augmented cancer cell plasticity, skewing luminal B tumors towards increased expression of basal-like features, in association with increased resistance to hormone therapy. Hence, these two closely related paralogs play distinct roles in protection against breast cancer; tumors with reduced expression of either LATS1 or LATS2 may rewire signaling networks differently and thus respond differently to anticancer treatments.

Citing Articles

Breast cancer genomic analyses reveal genes, mutations, and signaling networks.

Manjunath G, Sharma S, Nashier D, Vasanthaiah S, Jha S, Bage S Funct Integr Genomics. 2024; 24(6):206.

PMID: 39496981 DOI: 10.1007/s10142-024-01484-y.


New Insights into YAP/TAZ-TEAD-Mediated Gene Regulation and Biological Processes in Cancer.

Zhao Y, Sheldon M, Sun Y, Ma L Cancers (Basel). 2023; 15(23).

PMID: 38067201 PMC: 10705714. DOI: 10.3390/cancers15235497.


Inflammatory signaling pathways in the treatment of Alzheimer's disease with inhibitors, natural products and metabolites (Review).

Zheng Y, Zhang X, Zhang R, Wang Z, Gan J, Gao Q Int J Mol Med. 2023; 52(5).

PMID: 37800614 PMC: 10558228. DOI: 10.3892/ijmm.2023.5314.


Mechanisms underlying divergent relationships between Ca and YAP/TAZ signalling.

Khalilimeybodi A, Fraley S, Rangamani P J Physiol. 2022; 601(3):483-515.

PMID: 36463416 PMC: 10986318. DOI: 10.1113/JP283966.


Inactivation of LATS1/2 drives luminal-basal plasticity to initiate basal-like mammary carcinomas.

Kern J, Tilston-Lunel A, Federico A, Ning B, Mueller A, Peppler G Nat Commun. 2022; 13(1):7198.

PMID: 36443313 PMC: 9705439. DOI: 10.1038/s41467-022-34864-8.


References
1.
Liberato M, Nascimento A, Ayers S, Lin J, Cvoro A, Silveira R . Medium chain fatty acids are selective peroxisome proliferator activated receptor (PPAR) γ activators and pan-PPAR partial agonists. PLoS One. 2012; 7(5):e36297. PMC: 3359336. DOI: 10.1371/journal.pone.0036297. View

2.
Osborne C . Steroid hormone receptors in breast cancer management. Breast Cancer Res Treat. 1999; 51(3):227-38. DOI: 10.1023/a:1006132427948. View

3.
Subramanian A, Tamayo P, Mootha V, Mukherjee S, Ebert B, Gillette M . Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102(43):15545-50. PMC: 1239896. DOI: 10.1073/pnas.0506580102. View

4.
Tran B, Bedard P . Luminal-B breast cancer and novel therapeutic targets. Breast Cancer Res. 2012; 13(6):221. PMC: 3326541. DOI: 10.1186/bcr2904. View

5.
Demetri G, Fletcher C, Mueller E, Sarraf P, NAUJOKS R, Campbell N . Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci U S A. 1999; 96(7):3951-6. PMC: 22401. DOI: 10.1073/pnas.96.7.3951. View